Thyroid hormone (T3) has been shown to regulate the level of its receptor in a number of tissues and cell lines. Recently, proteins encoded by the protooncogene c-erbA have been identified as T3 receptors. In the rat, four c-erbA gene products have been isolated, three of which, r-erbAa-1, r-erbAB-1, and r-erbA13-2, encode biologically active T3 receptors; the fourth, r-erbAa-2, may play an inhibitory role in T3 action. The present work examines the molecular nature of T3 receptor autoregulation using probes specific for each c-erbA mRNA. Rats were rendered hypothyroid with propylthiouracil and then treated with either saline or T3. Northern blot analyses reveal marked tissue-specific and differential regulation of the multiple c-erbA mRNAs by T3. In the pituitary the levels of rerbA,8-1 mRNA increase, whereas the levels of the pituitaryspecific r-erbAf,-2 mRNA decrease with T3 treatment. In heart, kidney, liver, and brain the levels of r-erbAB-1 are unaffected by thyroidal status. The levels of both r-erbAa mRNAs decrease with T3 treatment in all tissues examined except for the brain, where there is no change. In addition, we find that changes in the mRNAs encoding specific subpopulations of T3 receptors do not always parallel changes in total nuclear T3 binding. Differential regulation of the specific c-erbA mRNA species could have important consequences for T3 action. (J.
Introduction
The magnitude of the cellular response to thyroid hormone (T3)' is related to the number of nuclear receptors present (1) .
It is therefore likely that physiologic or pharmacologic alterations in receptor number may modify the response of a tissue treatment causes a decrease in receptor number which, in turn, results in an attenuation in T3 responsiveness, as measured by growth hormone gene transcription (2) .
Numerous investigators have studied the effects of thyroidal status on rat T3 receptors, but the results have been conflicting. Pituitary receptor levels have been reported to increase (3) , decrease (4) , or remain unchanged (5) in response to T3 treatment. Similar inconsistencies exist in the literature concerning the effect ofthyroidal status on receptor number in rat liver (6, 7) . T3 receptors, encoded by the a and (3 c-erbA genes, are members of a superfamily of structurally related receptor proteins (8, 9) . The recent identification of multiple forms of the T3 receptor (10-18) sheds new light on the issue of receptor autoregulation. We have shown, for example, that changes in specific receptor subpopulations may not be reflected in a measurement of total receptor number in GH3 cells (14, 18, 19) .
In the rat, three putative biologically active T3 receptors have been identified, r-erbAa-1 (10), r-erbA#-l (13) , and rerbA13-2 (18) . In addition, a related molecule, r-erbAa-2, does not bind T3 (12, 14, 15) and may act to inhibit T3 action (20) .
r-erbAa-1, r-erbAa-2, and r-erbA#-1 are expressed to varying degrees in a number of rat tissues (14, 18) , whereas the expression of r-erbA13-2 is limited to the anterior pituitary gland (18) . We have examined the effects of T3 treatment on the levels of the various c-erbA gene products in pituitary as well as a number of other rat tissues. Our results show that there is tissue-specific and differential regulation of the r-erbA mRNAs by thyroid hormone, and suggest that measurement of total nuclear T3 binding is inadequate when examining alterations in T3 receptors.
Methods
Adult male Sprague-Dawley rats (125-150 g) were maintained on standard chow and water supplemented with 0.05% (wt/vol) propylthiouracil (PTU) for a 6-wk period. Six daily intraperitoneal injections of either saline (PTU only or hypothyroid group) or 20 ug/g body weight triiodothyronine (PTU + T3 or hyperthyroid group) were then administered. During the administration of the supraphysiologic replacement dose ofT3 both groups ofanimals were maintained on PTU treatment. The animals were killed by decapitation and their organs were removed, immediately frozen in liquid nitrogen, and stored at -70°C. Blood was collected from each animal and assayed for T3 to confirm thyroidal status.
The frozen tissues were homogenized and RNA was extracted using the guanidinium thiocyanate method (21). Northern blot analyses were performed by standard techniques (22) . The filters were hybridized with cDNA (growth hormone, actin, and spot-14 mRNAs) or cRNA (r-erbA mRNAs) probes labeled with 32P, typically to a specific activity of 5 derived from the 5' region of the cDNAs and have been previously
shown to be specific for either the r-erbAf-l or r-erbAjB-2 species (18).
The r-erbAa probe is derived from the region common to the rerbAa-l and r-erbAa-2 mRNAs. We have previously determined the specificity of the 2.6-(a-2) and 5-kb (a-l) hybridizing bands (14 Results r-erbAB-l and r-erbAB-2 mRNA levels in pituitary glands of hypothyroid and hyperthyroid rats were determined using specific probes (18) . A representative Northern blot analysis demonstrating that the two d forms of r-erbA are differentially regulated by T3 in the pituitary is shown in Fig. 1 . After normalization for (3-actin mRNA, the r-erbAf3-l mRNA levels were shown to increase -3.5-fold (P < 0.025), whereas the r-erbA#3-2 levels decreased -50% (P < 0.005) from the hypothyroid to the hyperthyroid state. In agreement with previous work (24) , growth hormone mRNA levels increased -15-fold with T3 treatment.
In contrast to the changes seen in the pituitary, the levels of r-erbA8I-l mRNA were unchanged in brain, heart, and kidney as a function ofthyroidal status (Fig. 2) . In liver there appeared to be more variability in r-erbA3-expression. After correction for ,B-actin expression there was a tendency towards a decrease in r-erbA(-l mRNA levels with T3 treatment, although this was not statistically significant. Spot 14 mRNA was significantly increased in all livers from hyperthyroid rats (data not shown). In agreement with our previous studies (1 8j no hybridization corresponding to the r-erbAB-2 mRNA was detected in these nonpituitary tissues.
The r-erbAa-l (5 kb in size) and r-erbAa-2 (2.6 kb in size) mRNAs were also studied in these various rat tissues using a probe that hybridizes to both mRNAs (14) . Both the r-erbAa-I and r-erbAa-2 mRNA levels decreased with T3 treatment in all tissues studied with the exception of brain (Fig. 3) . The magnitudes of the decreases in r-erbAa-l were 65, 69, and 22% of hypothyroid levels in heart (P < 0.005), kidney (P < 0.005), and pituitary (P < 0.1), respectively. The decreases in rerbAa-2 mRNA were similar in magnitude to those seen with r-erbAa-l: 86% in heart (P < 0.005), 63% in kidney (P < 0.005), and 22% in pituitary (P < 0.1). The levels of both r-erbAa mRNAs remained constant in brain regardless of thyroidal status. Rat liver contains minimal amounts of rerbAa mRNAs; hence, a quantitative analysis was not possible. A 6-kb band, which we have previously shown to hybridize to both a-l-and a-2-specific probes (14) and which may represent an unspliced heteronuclear RNA, is evident in all rat tissues examined. The level of this 6-kb band also decreases with T3 treatment.
T3 binding studies were performed using nuclear extracts from pituitary glands of hypothyroid and hyperthyroid animals. Fig. 4 illustrates Scatchard analyses showing no change in the affinity constant (Kd = 0.7 nM) between the two groups.
Heart Kidney Brain Liver Figure 2 . Effect of thyroidal Our results indicate that thyroidal status differentially affects the expression of the various r-erbA mRNAs, and possibly their products, and that these effects differ from tissue to tissue. In the pituitary gland, as in GH3 cells (18) , r-erbA#-1 levels increase, whereas r-erbAft-2 levels decrease with T3 treatment. The increase in r-erbA#-l mRNA appears to be greater than in the GH3 cell model. This difference may relate to characteristics of the GH3 cell culture system or to differences in experimental protocol, such as the duration and magnitude of T3 exposure. However, in kidney, heart, brain, and liver, the levels of r-erbAf3-1 are unaffected by thyroidal status.
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The levels of both r-erbAa species decrease with T3 treatment in all tissues examined with the exception of brain. In each tissue, the magnitudes of the change in the two r-erbAa mRNA species were approximately the same. This downregulation of r-erbAa mRNAs is similar to what we have previously shown in GH3 cells (14, 19) . The magnitude of the r-erbAa mRNA decreases were greatest in heart and kidney and less in pituitary. Table I summarizes the effects of thyroidal status on the r-erbA species in the rat tissues we have examined. Ofnote, the absence of a T3 effect on any r-erbA mRNA in brain is consistent with its general lack of responsiveness to T3 and may relate to the abundance of the mRNA encoding r-erbAa-2, a potential inhibitor ofT3 action (20) . Table I also illustrates that the pituitary appears to be unique both in its expression of the r-erbAf3-2 mRNA and the induction of the r-erbA,-l mRNA with T3 treatment. These data suggest a possible role for rerbAfl-2 in the regulation of r-erbA/#-1 expression.
The slight increase in T3 binding in pituitary nuclear extracts from T3-treated rats is consistent with data from the Northern analyses, inasmuch as the changes in specific r-erbA mRNAs are in different directions. The decrease in T3 binding seen in the GH cell model compared with the data we obtained in rat pituitary may relate to the relatively greater increase in r-erbA#-1 mRNA and more moderate decrease in r-erbAf3-2 mRNA in this tissue in the whole animal. Since the total T3 Although it is difficult to estimate relative abundances of different mRNAs by Northern analyses, it appears that rerbAB-l is more abundant than r-erbAac-l in the tissues that we have examined. Thus, the lack of a difference in T3 binding in hypo-versus hyperthyroid nonpituitary tissues correlates well with the lack of change in r-erbA3-I mRNA levels. However, if the specific subpopulations of T3 receptors serve different functions, such as interacting with different target genes, then the decrease in r-erbAa-1 mRNA could have great consequences for T3 action despite the fact that total T3 binding does not appear to change. Similarly, the regulation of the mRNA encoding the non-hormone binding r-erbAa-2 could be important for T3 action, since the protein may function to inhibit T3 responsiveness.
It is possible that factors other than thyroidal status influenced our results. Fasting that leads to significant weight loss, for example, has been shown to be associated with decreased hepatic T3 receptor number (25) . Although we did not specifically control for food intake, the two groups of rats in our study were of similar weight.
Autoregulation of receptors is a common biological phenomenon seen in higher organisms (26). Various members of the thyroid/steroid hormone receptor superfamily have been shown to either increase or decrease in response to treatment with their cognate hormones (27) (28) (29) (30) (31) (32) (33) . Similar to what we have shown with T3 receptors, the a and ,3 retinoic acid (RA) receptors are differentially regulated by exposure to RA (31). Regulation of the estrogen and glucocorticoid receptors have been shown to be tissue specific (32, 33) . Studies are in progress to determine ifthe effects ofT3 on r-erbA mRNA levels are at the transcriptional level, as is the case with the estrogen and (l-RA receptors (30, 31 ).
Our present model of T3 action includes the interaction of T3 with multiple forms of its receptor, as well as a related protein that appears to inhibit T3 action. The present studies demonstrate that experimental conclusions based on total T3 nuclear receptor number may be misleading, since receptor subpopulations can be regulated differentially. Further work is clearly needed to determine the role that each of the r-erbA gene products plays in thyroid hormone action.
